A potential breakthrough treatment for many types of human cancers, COTI-2 is a clinical stage, novel small molecule activator of misfolded mutant p53 proteins.
Chemsas® is an advanced drug discovery platform that identifies compounds with a higher probability of clinical and commercial success.
Targeted therapeutics focusing on innovative cancer treatments as well as drug candidates for the treatment of serious diseases where current therapies are lacking or ineffective.
Critical Outcome Technologies represents a multi-pronged approach to value creation in the biopharmaceutical space. In addition to a potential breakthrough treatment for many cancers, COTI has a robust pipeline of compounds, R&D; collaborations and other applications of its core technology.